Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | G6PD | P11413 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | MPI | P34949 | 1/20 | 0.34 |
| ▸ | EP300 | Q09472 | 1/20 | 0.34 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.34 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16088864 | 0.92 | CHRNA7 (0.33) | ALDH1A1KDM4EMAPTGAAKMT2A | |
| SCHEMBL15942719 | 0.86 | KDM4C (0.32) | ALDH1A1KDM4EGAAKMT2AMEN1 | |
| SCHEMBL13282849 | 0.86 | HRH4 (0.43) | — | |
| SCHEMBL761081 | 0.86 | LMNA (0.38) | ALDH1A1KDM4EPKMKMT2AMEN1 | |
| SCHEMBL13212356 | 0.85 | CHRNA7 (0.34) | ALDH1A1KDM4EGAAKMT2AMEN1 | |
| SCHEMBL15942720 | 0.85 | KDM4E (0.31) | ALDH1A1KDM4EGAAKMT2AMEN1 | |
| SCHEMBL13212352 | 0.85 | ALDH1A1 (0.32) | ALDH1A1KDM4EKMT2AHPGDHSD17B10 | |
| SCHEMBL10072565 | 0.84 | HTR3A (0.31) | ALDH1A1KMT2AHTR3ANPSR1PPARG | |
| SCHEMBL9927991 | 0.84 | HTR3A (0.31) | ALDH1A1GAAHTR3A | |
| SCHEMBL10072567 | 0.84 | HTR3A (0.31) | ALDH1A1GAAHTR3AKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9969730-B2 | Stable SNS-595 compositions and methods of preparation | SUNESIS PHARMACEUTICALS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-9839630-B2 | Method of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid | SUNESIS PHARMACEUTICALS, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170226104-A1 | STABLE SNS-595 COMPOSITIONS AND METHODS OF PREPARATION | SUNESIS PHARMACEUTICALS INC (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170035741-A1 | METHOD OF PREPARING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID | SUNESIS PHARMACEUTICALS, INC. | 2017-02-09 | — | — | US | disclosed |
| US-9469635-B2 | Stable SNS-595 compositions and methods of preparation | SUNESIS PHARMACEUTICALS, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-20140275547-A1 | STABLE SNS-595 COMPOSITIONS AND METHODS OF PREPARATION | SUNESIS PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-8802719-B2 | Method of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid | SUNESIS PHARMACEUTICALS, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-20140171660-A1 | METHOD OF PREPARING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID | SUNESIS PHARMACEUTICALS, INC. | 2014-06-19 | — | — | US | disclosed |
| US-8586601-B2 | Stable SNS-595 compositions and methods of preparation | SUNESIS PHARMACEUTICALS, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-8138202-B2 | Stable SNS-595 compositions and methods of preparation | SUNESIS PHARMACEUTICALS, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20110086876-A1 | STABLE SNS-595 COMPOSITIONS AND METHODS OF PREPARATION | SUNESIS PHARMACEUTICALS, INC. | 2011-04-14 | — | — | US | disclosed |
| US-20110082169-A1 | Stable SNS-595 Compositions and Methods of Preparation | SUNESIS PHARMACEUTICALS, INC. | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082169-A1 | Stable SNS-595 Compositions and Methods of Preparation | NES, NCDN, NCL | ALDH1A1 3346/4885KDM4E 4228/4885MAPT 1995/4885 |
| US-20140275547-A1 | STABLE SNS-595 COMPOSITIONS AND METHODS OF PREPARATION | NES, NCDN, NCL | ALDH1A1 3346/4885KDM4E 4228/4885MAPT 1995/4885 |
| US-20170035741-A1 | METHOD OF PREPARING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID | CYP7A1, MT-ND1, DNM1 | ALDH1A1 66/4885KDM4E 2201/4885MAPT 1587/4885 |
| US-20140171660-A1 | METHOD OF PREPARING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID | CYP7A1, DNM1, MT-ND1 | ALDH1A1 78/4885KDM4E 2190/4885MAPT 1666/4885 |
| US-20110086876-A1 | STABLE SNS-595 COMPOSITIONS AND METHODS OF PREPARATION | NES, NCDN, NCL | ALDH1A1 3346/4885KDM4E 4228/4885MAPT 1995/4885 |
| US-20170226104-A1 | STABLE SNS-595 COMPOSITIONS AND METHODS OF PREPARATION | NES, NCDN, NCL | ALDH1A1 3346/4885KDM4E 4228/4885MAPT 1995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.